Interpersonal behavior and experience of patients with chronic depression or borderline personality disorder: Examining the long-term effectiveness of disorder-specific psychotherapy regarding biological (oxytocin), (epi-)genetic and clinical variables

Recruiting

• Conditions: DSM-5: 300.4 Persistent depressive disorderDSM-5 301.83 borderline personality disorder; F33; F34.1; F60.31; Recurrent depressive disorder; Dysthymia

• Registration Number: DRKS00019821
• Lead Sponsor: Klinikum der Universität München, Campus Großhadern

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-05-28
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Participation in the DBT-program or in the CBASP program for patients with BPD or CD (according to DSM-5).
Psychologically and physiologically healthy participants, without any psychiatric illness in the past (participant does not fulfill any diagnosis in the SKID-5-CV and does not fulfill more than three criteria for any of the personality disorders in the SKID-5-PD).

Exclusion Criteria

Patient groups:
- Acute suicidal ideation
- Any unstable or not sufficiently treated accompanying somatic disorder (e.g. hypothyroidism orhypertonia), including acute or chronic infections and autoimmune diseases
- Pregnancy

Control group:
- Any unstable or not sufficiently treated concomitant somatic disorders (e.g. hypothyroidism or hypertonia), including acute or chronic infections and autoimmune diseases
- Previous participation at any study including the cyberball paradigm
- Current or previous (within the last 10 years) intake of psychiatric drugs (exception: benzodiazepine, z-medication)
- Pregnancy and breastfeeding period
- Previous psychiatric treatment
- Previous psychotherapeutic treatment (within the last 10 years)
- Excessive smoking (> 1,5 packages/day)
- Noticeable score on the BDI (> 12) and on the SKID-5-CV/PD-Screenings

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in MADRS-Score / BDI-II / BSL-23 after ten weeks

Secondary Outcome Measures

Name	Time	Method
Change in depressive and borderline symptoms, interpersonal problems and interpersonal impact, life quality, loneliness, social network index, attachment style, working alliance, plasma oxytocin levels, epigenetic regulation of oxytocin after 6 and 12 months.